Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2014 Sep 19;13(11):2653–2661. doi: 10.1158/1535-7163.MCT-14-0132

Figure 4.

Figure 4

Pre-treatment with paclitaxel enhances RIT anti-tumor response. Female athymic nude mice were inoculated with tumor cells at time 0. Animals were treated with vehicle, RG7787 with IP vehicle injection, paclitaxel with IV vehicle injection, or paclitaxel and RG7787 combination. Paclitaxel (50 mg/kg) was administered by IP injection on days marked with long arrows. RG7787 (2.5 mg/kg) was administered IV on days indicated by short arrows. Mean tumor volumes are indicated by the markers. For vehicle control five mice were followed. Results of both experiments were confirmed by repeat. (A) HCC70 TNBC tumor xenografts. There is a statistically significant difference between paclitaxel and combination treatment beginning at day 13 (p ≤ 0.001, n = 6 per treatment group). (B) MKN28 gastric cancer tumor xenografts. There is a statistically significant difference between paclitaxel and combination treatment beginning at day 10 (p ≤ 0.001, n= 8 per treatment group).